Skip to main content
. 2015 Jul 21;112(31):9734–9739. doi: 10.1073/pnas.1505420112

Fig. 5.

Fig. 5.

Application of CRANAD-3 for monitoring therapeutic effects of drug treatments. (A) In vivo imaging of APP/PS1 mice with CRANAD-3 before and after treatment with the BACE-1 inhibitor LY2811376. (B) Quantitative analysis of the imaging in A (n = 4). (C) Representative images of 4-mo-old APP/PS1 mice after 6 mo of treatment with CRANAD-17. (Left) Age-matched WT mouse. (Center) Control APP/PS1 mouse. (Right) CRANAD-17–treated APP/PS1 mouse. Note that the NIRF signal from the CRANAD-17–treated APP/PS1 mouse (Right) is lower than the signal from the nontreated control APP/PS1 mouse (Center). (D) Quantitative analysis of the imaging in C (n = 5). (E) ELISA analysis of total Aβ40 from brain extracts. (F) Analysis of plaque counting. (G) Representative histological staining with thioflavin S. (Left) CRANAD-17–treated mouse. (Right) Control. *P < 0.05, **P < 0.01, ***P < 0.005.